Humanin is a short peptide investigated for the way cells survive particular stresses and communicate mitochondrial state. Its discovery began with neuronal-cell experiments related to Alzheimer's disease; later work examined cell-death proteins, cell-surface receptors and circulating measurements in human cohorts. Researchers have identified specific survival mechanisms in laboratory systems and associations with age or disease in people. Many animal interventions use modified humanin analogues, making their exact structure part of the explanation of each result. Hashimoto and colleagues (2001), Hashimoto and colleagues (2009).
Overview
Molecular profile
Forms and derivatives
Humanin-G / HNG / S14G-humanin
Glycine replaces serine at residue 14. Used in animal intervention and receptor/structure-function work.
HNGF6A
HNG with alanine replacing phenylalanine at residue 6. The engineered analogue was examined in rodent pharmacokinetic comparisons as a form with altered IGFBP-3 binding.
The commonly studied humanin form contains 24 amino acids, with the sequence MAPRGFSCLLLLTSEIDLPVKRRA. FDA's substance record describes this precise peptide. Humanin is associated with a short open reading frame in the mitochondrial 16S ribosomal-RNA region. An open reading frame is a stretch of genetic information that can specify a peptide; identifying such a sequence and establishing how a cell produces its product are connected biological questions. FDA humanin identity record, Yen and colleagues (2020).
Humanin's original discovery paper has a substantive correction. The authors clarified that their experiments had not established natural production of the peptide in vivo or the genomic origin of the isolated cDNA. That correction qualifies the original origin interpretation while leaving the experimental cell-survival observations available for evaluation. Later endogenous measurements need to be assessed through their own methods. Hashimoto and colleagues, correction (2001).
HNG and related analogues
Humanin-G, or HNG, is the S14G analogue: glycine replaces serine at residue 14. HNGF6A contains an additional change at residue 6 and was designed to alter interaction with insulin-like growth factor binding protein 3, or IGFBP-3. These structures appear in experiments investigating activity and exposure. Their substitutions help researchers test which parts of humanin determine a response; each tested analogue retains its own evidence scope. Chin and colleagues (2013).
Uses and research areas
The early neuronal work asked whether a small peptide could reduce cell death caused by familial Alzheimer's-related gene products or amyloid-beta. Other studies examined the proteins that move a cell toward apoptosis, the regulated process through which cells dismantle themselves. These experiments concern survival mechanisms in defined systems. Hashimoto and colleagues (2001), Guo and colleagues (2003).
Aging and metabolic research asks a broader question: whether endogenous humanin measurements accompany a particular physiological state. Studies of centenarians' offspring, older adults and disease-defined groups compare naturally occurring measurements. Exercise studies also examine changes in the body's own peptide-associated signals. These approaches can identify associations and responses that guide further experiments, including the possibility that a measurement reflects compensation for stress. Yen and colleagues (2020), Conte and colleagues (2021), von Walden and colleagues (2021).
Mechanism of action
Guo and colleagues studied Bax, a protein that can promote apoptosis by moving from the fluid interior of a cell to mitochondrial membranes. Humanin interacted with Bax and inhibited that movement. Experiments with isolated mitochondria also showed reduced release of cytochrome c, one of the signals involved in the cell-death sequence. This supplies a direct mechanistic explanation for survival under a Bax-associated insult. It also makes the identity of the protected cell consequential: maintaining the survival of a stressed neuron and maintaining the survival of a malignant cell have different biological implications. Guo and colleagues (2003).
Hashimoto and colleagues investigated a cell-surface route. Their loss-of-function and binding experiments implicated a receptor complex involving CNTFR-alpha, WSX-1 and gp130. Reducing or interfering with these components reduced the observed response in neuronal-cell systems, while reconstituted binding experiments supported a physical interaction among the components. The work linked extracellular humanin to STAT3 signaling, a pathway through which cells alter survival-related activity and gene expression. It explains how a signal outside a neuron can engage machinery governing survival inside that cell. Hashimoto and colleagues (2009).
Pharmacokinetics
A 2013 paper titled Pharmacokinetics and Tissue Distribution of Humanin and Its Analogues in Male Rodents primarily tested HNG and HNGF6A. The mouse comparison included wild-type animals and mice lacking IGFBP-3; a separate rat arm assessed HNG in plasma and tissues after intraperitoneal administration. Humanin-associated levels were measured by ELISA, an antibody-based assay. The circulating signal declined more slowly in normal mice given HNGF6A and in mice lacking IGFBP-3 given HNG than in normal mice given HNG. Chin and colleagues (2013).
The longer circulating response depended on the analogue and on whether the mice produced IGFBP-3. This points to binding partners as well as sequence as contributors to peptide exposure. The ELISA measured humanin-associated signal, making the assay's ability to recognize parent peptide, analogue and fragments relevant to interpreting the time response. Human exposure after administration of native humanin remains uncharacterized in the clinical literature reviewed here.
Research findings
Selective neuronal-cell protection
Hashimoto and colleagues identified a cDNA through functional screening for factors that rescued cultured neuronal cells. Humanin reduced death associated with several familial Alzheimer's-related insults and amyloid-beta. Protection did not extend to the tested polyglutamine Q79 and mutant superoxide-dismutase insults, and activity depended on the peptide's structure. The responsive and unresponsive conditions helped narrow the cell-death processes that subsequent Bax and receptor experiments could investigate. Hashimoto and colleagues (2001).
Lifespan and health measurements across distinct models
Yen and colleagues combined several kinds of evidence in a 2020 paper. Humanin overexpression increased lifespan in a worm model. In the mouse treatment arm, middle-aged female mice received the HNG analogue; some metabolic and body-composition measurements improved, but lifespan did not significantly increase. The human comparison measured circulating humanin in 18 offspring of centenarians and 19 age-matched controls and found higher levels in the offspring group. That cohort observation describes an association with familial longevity. Its participants received no humanin intervention. Yen and colleagues (2020).
Human biomarkers vary with disease and study setting
Conte and colleagues examined 569 plasma samples across healthy older controls, centenarians' offspring, Alzheimer's disease and type 2 diabetes groups. Humanin was lower in the Alzheimer's group, while the diabetes groups did not show the same pattern. In healthy participants, plasma humanin was positively associated with age. That direction differs from age-related declines described in other selected cohorts and species, which complicates a universal interpretation of higher or lower levels. Group selection, disease, biological compartment and assay method all belong in interpreting the observation. Conte and colleagues (2021).
An independent exercise experiment randomized 30 people to endurance exercise, resistance exercise or a control condition. Circulating humanin rose after endurance exercise and did not rise significantly after resistance exercise. Baseline peptide measurements did not correlate with the tested fitness outcomes. The results connect an endogenous peptide response with a particular type of exertion. von Walden and colleagues (2021).
More recently, Liao and colleagues examined humanin and MOTS-c in atrial fibrillation, an irregular heart rhythm. They found lower humanin measurements in affected atrial tissue. A separate blood comparison of 39 patients with atrial fibrillation and 39 controls found slightly higher plasma humanin, with no significant relationship to NT-proBNP, a marker of cardiac strain. The tissue and blood findings show why the sampled compartment matters when interpreting a humanin measurement. Separate mouse and cardiac-cell experiments used HNG, the modified humanin analogue, and MOTS-c. HNG reduced inducibility of the rhythm disturbance and several remodeling measures in the mouse model. Liao and colleagues (2026).
Safety and tolerability
The human cohorts described here measured endogenous peptide; they provide no adverse-event estimate for administering a humanin product. Humanin has no FDA-approved therapeutic indication identified in the current sources, and an administered-human safety profile remains unestablished. FDA's substance identifier records chemical identity independently of regulatory approval. FDA identity record.
There is a concrete preclinical reason to assess the context of cell protection carefully. Moreno Ayala and colleagues studied experimental triple-negative breast cancer. Added humanin protected tumor cells against apoptotic stimuli, and systemic humanin in tumor-bearing mice promoted tumor progression and impaired chemotherapy's antitumor and antimetastatic effects. The study raises a tissue- and disease-specific concern; it does not provide a numerical cancer-risk estimate for people. Moreno Ayala and colleagues (2020).
What the research means
Humanin is a useful link between mitochondrial signaling, cellular stress and survival. Its molecular studies have enough detail to support specific explanations, while the cohort studies show that circulating measurements reflect a complex physiological context. The null mouse lifespan finding and differing human age associations make the interpretation more informative than a simple replacement or longevity claim.
Clinical development would need to resolve exposure and identity before asking whether a particular preparation improves a meaningful human outcome. Native humanin, HNG and other analogues may answer related questions, but substituting one structure for another changes the material under evaluation. Long-term assessment must also examine whether protecting particular cells creates unwanted effects elsewhere.
FAQs
Is HNG simply another name for humanin?
HNG is the S14G analogue, which changes one residue of the parent sequence. The substitution can affect measured activity and exposure, so HNG experiments need their own material label. Chin and colleagues (2013).
What did the centenarian-family comparison measure?
Researchers measured the body’s own circulating humanin in 18 people whose parents were centenarians and 19 age-matched controls. Levels were higher in the centenarians’ offspring. This associates a blood measurement with family longevity; nobody in that comparison received humanin as treatment. Yen and colleagues (2020).
Did the HNG mouse intervention extend lifespan?
The 2020 study reported changes in metabolic and body-composition measurements without a significant mouse-lifespan increase. The lifespan gain occurred in a separate transgenic worm experiment. Yen and colleagues (2020).
Why can a cell-protective effect create a safety concern?
The identity of the surviving cell matters. Humanin supported tumor-cell survival and impaired chemotherapy effects in an experimental triple-negative breast-cancer model. Those findings warrant direct safety investigation; they do not quantify a cancer risk for treated humans. Moreno Ayala and colleagues (2020).
What changed in the discovery paper's correction?
The authors clarified that the original experiments did not establish natural in-vivo peptide production or the genomic origin of the isolated cDNA. The cell-survival observations and later endogenous measurements should be evaluated through their respective methods. Hashimoto and colleagues' correction (2001).
Comparisons and related reading
MOTS-c belongs to the same broad mitochondrial-derived peptide research area but has a different sequence and a stronger emphasis on metabolic stress responses. Elamipretide studies mitochondrial membrane biology through a separate molecular design and clinical development program. Semax provides a useful comparison for reading neuroprotection experiments alongside small clinical reports.
References
The bibliography credits the original discovery and its correction, molecular experiments, human observations, analogue pharmacokinetics and the experimental safety finding.
Specifies the 24-residue peptide and formula and explains that a substance identifier does not imply regulatory approval.
Reports structure-dependent survival in selected neuronal-death models and lack of protection in the Q79 and mutant-SOD1 conditions.
Clarifies what the discovery established about natural peptide production and the isolated cDNA's genomic origin.
Demonstrates Bax interaction, inhibited movement to mitochondrial membranes and reduced cytochrome-c release in experimental systems.
Uses receptor loss-of-function and binding experiments to link neuronal protection with CNTFR/WSX-1/gp130 and STAT3 activity.
Examines HNG/HNGF6A after intraperitoneal administration in mice and HNG tissue distribution in rats, using ELISA rather than a native-human exposure measurement.
Separates transgenic worm survival, HNG mouse health measurements and the small endogenous centenarian-offspring comparison; mouse lifespan did not increase significantly.
Reports disease-specific endogenous plasma patterns, including lower humanin in Alzheimer's disease and a positive age association in healthy participants.
Randomizes 30 participants across endurance, resistance and control conditions; reports a significant humanin response and a MOTS-c trend after endurance exercise.
Examines humanin in blood and atrial tissue, finding slightly higher plasma levels alongside lower tissue levels, then tests HNG and MOTS-c in separate animal and cell models.
Reports tumor-cell protection and impaired chemotherapy activity after systemic humanin in tumor-bearing mice, identifying a concrete context-specific safety concern.
Glossary
- Apoptosis
- A regulated cellular process through which cells dismantle themselves.
- Bax
- A protein involved in triggering mitochondrial steps of apoptosis.
- Cytochrome c
- A mitochondrial protein whose release can participate in cell-death signaling.
- STAT3
- A signaling and transcription-regulating protein involved in several survival responses.
- Open reading frame
- A stretch of genetic information capable of specifying a peptide.
- Endogenous
- Produced within the organism, as distinct from a substance added experimentally.
- ELISA
- An antibody-based assay used to measure a target-associated signal.
- IGFBP-3
- Insulin-like growth factor binding protein 3, examined as a humanin-analogue binding partner.